trial · primary record
TruSight Oncology
Inherited Bone Marrow Failure Syndrome
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 71 |
| Primary completion | 2027-10-30 |
| Primary endpoint | Determine the safety of imatinib in participants with pathogenic or likely pathogenic germline RUNX1 mutations during the dose expansion phase |
| Registry ID | NCT06090669 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:48.677Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06090669
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.